Pharm
Intranasal Dihydroergotamine
search
Intranasal Dihydroergotamine
, Migranal, Atzumi Nasal Powder Inhaler
See Also
Dihydroergotamine
Migraine Abortive Management
Indications
Migraine Abortive Management
Rarely used in modern U.S.
Migraine Management
(largely replaced by
Triptan
s)
Contraindications
See
Dihydroergotamine
Mechanism
See
Dihydroergotamine
Medications
Intranasal Dihydroergotamine
Migranal Nasal Spray: 0.5 mg per spray
Atzumi Nasal Powder Inhaler 5.2 mg/device
Precautions
Give first dose in health care facility in those with
Cardiovascular Risk Factor
s
Ergotamine
s have been replaced by
Triptan
s for multiple reasons
Low oral
Bioavailability
High risk for
Medication Overuse Headache
Common associated
Nausea
and
Vomiting
Serious adverse
Drug Interaction
risk
Dosing
Adults
Migranal
Prepare sprayer by inserting ampule and prime pump (4 squeezes before first use)
Use one spray each nostril
May repeat x1 after 15 minutes (Total dose = 2mg)
Maximum
Day: 6 sprays (3 mg/day)
Weekly: Twice per week or 8 sprays/week (4 mg/week)
Atzumi Nasal Powder Inhaler
Setup device (no priming needed)
Spray one device into 1 nostril
May repeat 1 spray into the same single nostril after 1 hour
Maximum
Day: 2 sprays (10.4 mg/day)
Weekly: 4 dose maximum
Monthly: 12 dose maximum
Adverse Effects
Rhinitis
Nausea
Taste perversion
Safety
Avoid in Pregnancy (Pregnancy Category X)
Avoid in
Lactation
Efficacy
Significant
Migraine
response in 30 minutes
Migranal: 70%
Placebo
: 28%
Reference
Gallagher (1996) Arch Neurol 53:1285-91 [PubMed]
Advantages
Lasts longer than intranasal
Imitrex
Rebound Headache
less common than
Imitrex
Rebound Headache
Incidence
: 15% within 24 hours
Less expensive than Intranasal
Imitrex
($16/dose)
Disadvantages
Does not work as fast as intranasal
Imitrex
More complicated to use than intranasal
Imitrex
Resources
Intranasal Dihydroergotamine (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=977de209-c53a-4cb4-9f3f-1e850600a9dc
Type your search phrase here